Journal issues > Issue 1, February 2020 > Highlights in acute leukaemia

Highlights in acute leukaemia

Summary

This article will summarise the key studies in the field of acute leukaemia presented at the 2019 annual meeting of the American Society of Hematology (ASH). The selected abstracts in the field of acute myeloid leukaemia (AML) mainly focus on precision medicine, measurable residual disease (MRD) and maintenance treatment. In addition, results of the phase I trial using CD19/CD22 bispecific CAR T cells in paediatric and adult patients with acute lymphoblastic leukaemia (ALL) will be discussed.

(BELG J HEMATOL 2020;11(1):18–20)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top